Navigation Links
Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results
Date:5/4/2011

002 White Paper and related implementation guidance.  A reconciliation of net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders in accordance with United States generally accepted accounting principles ("GAAP") to FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders is included in the financial information accompanying this press release.  The primary reconciling items between GAAP net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders and FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders is depreciation and amortization expense and gain on sales of property. Depreciation and amortization expense for the three months ended March 31, 2011 and 2010 was $36,707,000 and $29,738,000, respectively.  Net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders for the first quarter of 2011 was $24,365,000, or $0.44 per share (diluted), compared to net income attributable to Alexandria Real Estate Equities, Inc.'s common stockholders of $20,542,000, or $0.47 per share (diluted), for the first quarter of 2010.  

The following table summarizes the significant items that impacted FFO (diluted) during each period presented (dollars in thousands, except per share data):Three Months Ended3/31/1112/31/109/30/106/30/103/31/10FFO attributable to Alexandria Real Estate Equities, Inc.'s common stockholders – numerator for FFO per share (diluted), as reported$
,636$
58,474$
53,862$
9,840$
53,980Loss on early extinguishment of debt2,4952,3721,30041,496-Assumed conversion of 8% unsecured convertible notes (1)---3,560-Impact of unvested restricted stock awards(21)(20)(11)(333)-FFO (diluted), as adjusted$
3,110$
,826$
55,151$
54,563$
53,980Weighted average shares of common stock outstanding for calculating FFO per share attributable to Alexandria Real Estate Equities, Inc.'s
'/>"/>

SOURCE Alexandria Real Estate Equities, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community
2. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
3. Alexandria Real Estate Equities, Inc. Provides Update
4. Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock
5. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
6. Alexandria Real Estate Equities, Inc. Announces Pricing of Public Follow-On Offering of 7,000,000 Shares of Common Stock
7. Deals keep Coming in Medical real Estate
8. Millions Flowing into Medical Real Estate
9. Life Sciences Real Estate Outperforming Other Sectors
10. Miami Beach Real Estate Attorney Opens Miami Real Estate Brokerage for International Luxury Miami Beach Condo Buyers From Distressed Sellers
11. Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for ... advancing knowledge and research in reproductive medicine. In ... a seat on the executive board and will have ... , Dr. Hill has actively supported ASRM since 1984 ...
(Date:12/24/2014)... , December 23, 2014 ... Algeria , out today and available for free download ... actors driving change and growth in the sector today. ... scored notable successes has been in developing a homegrown pharmaceutical ... percent local production still remains some way off. A cursory ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Colo., Oct. 9 Replidyne, Inc.,(Nasdaq: RDYN ) ... and,webcast on Tuesday, October 30, 2007 at 4:45 P.M. ... in the conference call by,dialing 800-435-1261 (domestic) or 617-614-4076 ... the conference call will be available approximately one,hour after ...
... of Clinical Programs, PALO ALTO, Calif., Oct. ... a late-stage biotechnology company that,develops central nervous system ... be a presenting company at the 4th,Annual BIO ... at the,Palace Hotel of San Francisco. The company,s ...
... Oct. 8 Inverness Medical,Innovations (Amex: IMA ) ... Agreement with Panbio Ltd, an Australian company traded on,the ... will acquire all of the issued shares in Panbio ... values the issued share capital of,Panbio at approximately AUD ...
Cached Biology Technology:Replidyne to Announce Third Quarter 2007 Earnings 2Avicena to Present at 4th Annual BIO InvestorForum Conference 2Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Medicine have enhanced our understanding of the mechanism by ... food is converted into the energy required by cells. ... how organisms synthesize their major form of chemical energy. ... of PLoS Biology . Cells use the ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
... YORK and LEON, GUANAJUATO MEXICO, Aug. 18 Global ... and identity management market, announced today that it will ... Leon, Guanajuato, Mexico. Portoss, a Leon-based company, specializes in ... latest partnership between Portoss and the City of Leon ...
Cached Biology News:Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4Global Rainmakers Delivers World Class Iris Capability for Portoss 2Global Rainmakers Delivers World Class Iris Capability for Portoss 3
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
DTT, 25g...
...
Biology Products: